Radiation Oncology/Therapy: Page 430

Unexpected FDG-PET foci may signal subclinical tumors
By Jonathan S. Batchelor
FDG-PET is showing promise for detecting unexpected malignant and pre-malignant neoplasms other than the primary cancer for which the patient is scanned, according to the results of a study lead by Dr. Harry Agress, Jr. at Hackensack University Medical Center in New Jersey.
December 25, 2002
Breast cancer screening highlighted in oncology journal
By AuntMinnie.com staff writers
The January issue of Current Oncology Reports features several articles on breast cancer imaging.
December 19, 2002
NAS begins direct sales of brachytherapy seeds, posts year-end results
By AuntMinnie.com staff writers
Radiopharmaceutical developer North American Scientific (NAS) has begun selling its palladium-103 brachytherapy seeds through its new direct sales force.
December 16, 2002
Rotem expands capacity, plans EU and U.S. subsidiaries
By AuntMinnie.com staff writers
Isotope manufacturer Rotem Industries of Beer Sheva, Israel will be stepping up production of Hyox 18, its brand of oxygen-18 enriched water used in PET imaging.
December 11, 2002
AnorMed, Bristol-Myers Squibb link up
By AuntMinnie.com staff writers
Radiopharmaceutical developer AnorMed of Vancouver, British Columbia, has signed a licensing agreement with Bristol-Myers Squibb Medical Imaging of North Billerica, MA, for the use of its Hynic linker technology.
December 9, 2002
PET firm CTI introduces onsite cyclotron
By AuntMinnie.com staff writers
CTI Molecular Imaging introduced Eclipse ST at last week’s RSNA meeting. The product is a low-cost, self-shielded cyclotron for PET centers to manufacture their own FDG.
December 8, 2002
PET/CT preferred as whole-body scan for cancer detection
By Edward Susman
CHICAGO - Even though there are some cancers that can be seen better with whole-body MRI, researchers at this week’s RSNA meeting said they would prefer to use PET/CT fusion images to stage primary tumors.
December 5, 2002
MRI agent detects lymph node disease in prostate and renal cancers
Biopharmaceutical companies Advanced Magnetics of Cambridge, MA and Princeton, NJ-based Cytogen said studies presented at this week’s RSNA meeting indicate that investigational MRI contrast agent Combidex is able to distinguish malignant from normal lymph nodes in a variety of cancers, including prostate and renal tumors.
December 3, 2002
PET/CT fusion images help pinpoint cancer, therapy
By Edward Susman
CHICAGO - “What we are seeing with PET/CT just knocks your socks off,” said Dr. William Strauss, professor of radiology at the Weill Medical College of Cornell University, New York at an RSNA media briefing.
December 2, 2002
FDG tops gallium for imaging pediatric lymphoma
By Jonathan S. Batchelor
CHICAGO - When it comes to sensitivity and accuracy, the radionuclide of choice for imaging pediatric lymphoma is fluorodeoxyglucose.
November 30, 2002
'Questionable payments' topped $500,000, Syncor says
By AuntMinnie.com staff writers
Radiopharmaceutical firm Syncor International reported yesterday that "questionable payments" made by one of its overseas subsidiaries to customers in Taiwan exceeded $500,000 over the past five years.
November 20, 2002
Nomos opens Netherlands office
By AuntMinnie.com staff writers
Radiation therapy firm Nomos will establish an office in the Netherlands.
November 19, 2002
Previous Page
Page 430 of 464
Next Page